Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
476 stopped studies mapped to Malignant Ovarian Neoplasm and descendants · 86% state a reason
Over the 476 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | Phase 2 | withdrawn | Sep 16, 2008 | NewLink Genetics Corporation | Poor trial recruitment | Enrollment / accrual |
| NCT02441140 | Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis | N/A | terminated | May 12, 2015 | Dana-Farber Cancer Institute | Poor accrual | Enrollment / accrual |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Phase 1 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03286062 | VM110 in Detection of Microscopic Tumors: A Phase I Study | Phase 1 | terminated | Sep 18, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02769546 | Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis | — | terminated | May 11, 2016 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT01847677 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin(NOVA) | Phase 2 | terminated | May 7, 2013 | Grupo Español de Investigación en Cáncer de Ovario | not stated | Not stated |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | Phase 1 | withdrawn | Aug 23, 2018 | Lynkcell Inc. | Unable to recruit individuals for the study | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive…(HIPEC) | Phase 2 | withdrawn | Jul 2, 2015 | Krankenhaus Barmherzige Schwestern Linz | actually limited personnel ressources | Other (stated, no rule matched) |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial… | Phase 3 | withdrawn | Jun 9, 2008 | Gynecologic Oncology Group | Never opened to accrual, a GOG working number, not developed into a clinical trial. | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients… | Phase 2 | terminated | Oct 4, 2017 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT01766622 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | Phase 2 | withdrawn | Jan 11, 2013 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | Phase 1 | terminated | Jan 25, 2016 | Dana-Farber Cancer Institute | Company decided not to move forward with further accrual. | Enrollment / accrual |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian…(REPROVe) | Phase 1 / Phase 2 | withdrawn | Sep 13, 2017 | DelMar Pharmaceuticals, Inc. | Alternate study design for ovarian cancer under discussion | Other (stated, no rule matched) |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 24, 2012 | National Cancer Institute (NCI) | Study terminated due to slow/insufficient accrual. | Enrollment / accrual |
| NCT00484666 | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer(TopoTxt) | — | withdrawn | Jun 11, 2007 | Carilion Clinic | PI withdrew from study protocol participation | Other (stated, no rule matched) |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian… | Phase 1 | terminated | Feb 9, 2018 | Almac Discovery | to re-evaluate biomarker strategy for recruitment to Part 2 | Enrollment / accrual |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | terminated | Dec 16, 2013 | Medical University Innsbruck | production of IMP has stopped | Other (stated, no rule matched) |
| NCT01144442 | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First… | N/A | terminated | Jun 15, 2010 | Masonic Cancer Center, University of Minnesota | PI Request | Other (stated, no rule matched) |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With… | Phase 1 | terminated | Feb 20, 2015 | Millennium Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial,…(AL3818) | Phase 1 / Phase 2 | terminated | Sep 24, 2015 | Advenchen Laboratories, LLC | Sponsor termination | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01218490 | Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer(CARACO) | Phase 3 | suspended | Oct 11, 2010 | Institut Cancerologie de l'Ouest | qualitative analysis of the study database | Other (stated, no rule matched) |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary… | Phase 1 | terminated | Oct 24, 2016 | Verastem, Inc. | The study was terminated upon completion of escalation phase, prior to opening expansion cohorts | Other (stated, no rule matched) |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian…(SEASCAPE) | Phase 1 / Phase 2 | terminated | Oct 15, 2015 | Aduro Biotech, Inc. | Study was stopped due to low enrollment and lack of clinical activity. | Enrollment / accrual |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial… | Phase 2 | withdrawn | Oct 28, 2016 | M.D. Anderson Cancer Center | PI's request | Other (stated, no rule matched) |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With… | Phase 2 | terminated | Sep 14, 2012 | Incyte Corporation | Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual. | Enrollment / accrual |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent… | Phase 1 | withdrawn | Jan 30, 2014 | Fox Chase Cancer Center | study was never opened to accrual | Enrollment / accrual |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With… | Phase 1 / Phase 2 | terminated | Mar 9, 2010 | University Health Network, Toronto | Slow accrual | Enrollment / accrual |
| NCT02411565 | Fermented Wheat Germ Extract in Women With Ovarian Cancer | Early Phase 1 | terminated | Apr 8, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Drug manufacturing issues | Drug supply |
| NCT02539719 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With… | Phase 1 | terminated | Sep 3, 2015 | Stemcentrx | Strategic Considerations | Sponsor / business decision |
| NCT03206216 | Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN | N/A | terminated | Jul 2, 2017 | Stanford University | Business decision | Sponsor / business decision |
| NCT02530606 | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | N/A | withdrawn | Aug 21, 2015 | Stanford University | Efficacy | Efficacy / futility |
| NCT00102622 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant… | Phase 1 | terminated | Feb 1, 2005 | M.D. Anderson Cancer Center | Phase I/II study that did not progress to Phase II | Other (stated, no rule matched) |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Phase 2 | terminated | Feb 1, 2016 | Washington University School of Medicine | Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice | Enrollment / accrual |
| NCT00005645 | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not… | Phase 2 | withdrawn | May 26, 2004 | Genzyme, a Sanofi Company | not stated | Not stated |
| NCT02836028 | A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer | Phase 2 | withdrawn | Jul 18, 2016 | Pfizer | not stated | Not stated |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or… | Phase 2 | terminated | May 8, 2006 | Dana-Farber Cancer Institute | Early closure based on audit by study investigators after 3 patients died on study. | Other (stated, no rule matched) |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive… | Phase 1 / Phase 2 | terminated | May 29, 2009 | Dana-Farber Cancer Institute | Terminated due to unacceptable toxicity | Safety / toxicity |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00856453 | Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer | N/A | terminated | Mar 5, 2009 | Wake Forest University Health Sciences | slow accrual | Enrollment / accrual |
| NCT02878980 | An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of… | N/A | withdrawn | Aug 25, 2016 | City of Hope Medical Center | Feasibility issues | Other (stated, no rule matched) |
| NCT02872519 | PET Imaging of Ovarian Carcinoma With 18F-FSPG | Early Phase 1 | withdrawn | Aug 19, 2016 | Vanderbilt-Ingram Cancer Center | No funding | Funding |
| NCT00866723 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube… | Phase 2 | terminated | Mar 20, 2009 | Beth Israel Deaconess Medical Center | Recruitment has been terminated prematurely because of poor enrollment. | Enrollment / accrual |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian… | — | terminated | May 12, 2009 | Gynecologic Oncology Group | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 1, 2020source: clinicaltrials